Usefulness of vonoprazan,a potassium ion-competitive acid blocker,for primary eradication of Helicobacter pylori

被引:8
|
作者
Shinya Yamada [1 ]
Takumi Kawakami [1 ]
Yoshikazu Nakatsugawa [1 ]
Takahiro Suzuki [1 ]
Hideki Fujii [1 ]
Naoya Tomatsuri [1 ]
Hideki Nakamura [1 ]
Hideki Sato [1 ]
Yusuke Okuyama [1 ]
Hiroyuki Kimura [1 ]
Norimasa Yoshida [1 ]
机构
[1] Department of Gastroenterology,Japanese Red Cross Kyoto Daiichi Hospital
关键词
Helicobacter pylori; Eradication; Vonoprazan; Chronic gastritis; Potassium ion-competitive acid blocker;
D O I
暂无
中图分类号
R573 [胃疾病];
学科分类号
1002 ; 100201 ;
摘要
AIM To investigate usefulness of triple therapy with vonoprazan,a potassium ion-competitive acid blocker and antibiotics,for Helicobacter pylori(H.pylori) eradication.METHODS The H.pylori eradication rate was examined in 2507 patients(2055 undergoing primary eradication and 452 undergoing secondary eradication,excluding patients with subtotal gastrectomy) at the Japanese Red Cross Kyoto Daiichi Hospital from March 2013 to September 2015.For patients treated from March 2013 to February 2015,a proton pump inhibitor(PPI) was used to reduce acid secretion,while vonoprazan was used after March 2015.The success rates of the 2 regimens(PPI + amoxicillin + clarithromycin/metronidazole,or vonoprazan + amoxicillin + clarithromycin/metronidazole) were compared.RESULTS The success rate of primary H.pylori eradication was significantly higher in the vonoprazan group.When stratified by the underlying disease,a significant increase of the H.pylori eradication rate was observed in patients with chronic gastritis.A significantly lower H.pylori eradication rate was observed in younger patients compared to older patients in the PPI group,but there was no difference according to age in the vonoprazan group.On the otherhand,the success rate of secondary eradication was similar at approximately 90% in both groups.CONCLUSION Vonoprazan is very useful for primary eradication of H.pylori,and may become a first-line acid secretion inhibitor instead of PPIs.
引用
收藏
页码:550 / 555
页数:6
相关论文
共 50 条
  • [41] Association Between Vonoprazan and the Risk of Gastric Cancer After Helicobacter pylori Eradication
    Arai, Junya
    Miyawaki, Atsushi
    Aoki, Tomonori
    Niikura, Ryota
    Hayakawa, Yoku
    Fujiwara, Hiroaki
    Ihara, Sozaburo
    Fujishiro, Mitsuhiro
    Kasuga, Masato
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 22 (06) : 1217 - 1225.e6
  • [42] Severe Hypomagnesemia Associated with the Long-term Use of the Potassium-competitive Acid Blocker Vonoprazan
    Okamoto, Masaru
    Wakunami, Yu
    Hashimoto, Kyoji
    INTERNAL MEDICINE, 2022, 61 (01) : 119 - 122
  • [43] Radiographic Localization Study of a Novel Potassium-Competitive Acid Blocker, Vonoprazan, in the Rat Gastric Mucosa
    Matsukawa, Jun
    Kogame, Akifumi
    Tagawa, Yoshihiko
    Inatomi, Nobuhiro
    DIGESTIVE DISEASES AND SCIENCES, 2016, 61 (07) : 1888 - 1894
  • [44] In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker
    Yamasaki, Hitomi
    Kawaguchi, Naohiro
    Nonaka, Masami
    Takahashi, Junzo
    Morohashi, Akio
    Hirabayashi, Hideki
    Moriwaki, Toshiya
    Asahi, Satoru
    XENOBIOTICA, 2017, 47 (12) : 1027 - 1034
  • [45] Radiographic Localization Study of a Novel Potassium-Competitive Acid Blocker, Vonoprazan, in the Rat Gastric Mucosa
    Jun Matsukawa
    Akifumi Kogame
    Yoshihiko Tagawa
    Nobuhiro Inatomi
    Digestive Diseases and Sciences, 2016, 61 : 1888 - 1894
  • [46] The efficacy and safety of vonoprazan in quadruple therapy for Helicobacter pylori eradication: a comparative study
    Zhuang, Xiaoduan
    Jiang, Huiyue
    Jin, Dandan
    Sun, Meiling
    Wang, Zhenwu
    Wang, Xinying
    GASTROENTEROLOGY REPORT, 2023, 12
  • [47] Efficacy and safety of bismuth quadruple regimens containing minocycline and vonoprazan for eradication of Helicobacter pylori: Real-world evidence
    He, Qiyunna
    Ou, Yan
    Zhu, Huili
    Chen, Zhiqian
    Yang, Dailan
    Cheng, Qian
    Yin, Xia
    Xiao, Lina
    Cai, Lin
    Ye, Yan
    Xu, Xin
    Liao, Juan
    JGH OPEN, 2024, 8 (05):
  • [48] A Novel Potassium-Competitive Acid Blocker Improves the Efficacy of Clarithromycin-containing 7-day Triple Therapy against Helicobacter pylori
    Noda, Hisatsugu
    Noguchi, Seiji
    Yoshimine, Takashi
    Goji, Shigeki
    Adachi, Kazunori
    Tamura, Yasuhiro
    Izawa, Shinya
    Ebi, Masahide
    Yamamoto, Sayuri
    Ogasawara, Naotaka
    Funaki, Yasushi
    Sasaki, Makoto
    Kasugai, Kunio
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2016, 25 (03) : 283 - 288
  • [49] Clinical Study on the Eradication of Helicobacter pylori by Vonoprazan Combined with Amoxicillin for 10-Day Dual Therapy
    Yan, Kunfeng
    Dai, Xiaorong
    Li, Zhenxing
    Rong, Weiwei
    Chen, Lei
    Diao, Xinxin
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (03): : 240 - 247
  • [50] Vonoprazan-amoxicillin combination therapy for Helicobacter pylori eradication: an umbrella review of meta-analyses
    Syed, Saif
    Zehra, Fatima Tu
    Zaman, Maham
    Karmani, Vikash Kumar
    Saleem, Ayesha
    Khalid, Momina
    Asim, Syeda Nimrah
    Izhar, Sara
    Suhagiya, Gaurang Hasmukhbhai
    EGYPTIAN JOURNAL OF INTERNAL MEDICINE, 2024, 36 (01)